-
Your selected country is
Japan
- Change country/language
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- Japan (Japanese)
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Western blot analysis of PI3-Kinase p170 on rat brain lysate. Lane 1: 250, lane 2: 1:500, lane 3: 1:1000 dilution of PI3-Kinase p170.
WI38
BD Transduction Laboratories™ Purified Mouse Anti-PI3-Kinase p170
BD Transduction Laboratories™ Purified Mouse Anti-PI3-Kinase p170
Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
PI3-kinase phosphorylates the D-3 position of the inositol ring of phosphatidylinositol (PtdIns), producing PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3. PI3-Kinase is a heterodimer of an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic subunit (p110). However, this heterodimer is only one member of a larger family of proteins with similarity to the p110 subunit. These different PI3-kinase isoforms have been divided into three classes. Class I consists of p110α and p110β which bind the p85 subunit and associate with receptor tyrosine kinases. Class II contains 68D, cpk, and p170. These proteins all contain a C-terminal C2 domain and phosphorylate PtdIns and PtdIns(4)P, but not PtdIns(4,5)P2. Class III members only phosphorylate PtdIns to PtdIns(3)P and include the S. cerevisiae Vps34p and its human homologs. The first human Class II PI3-kinase to be described, p170, contains the characteristic C-terminal phosphoinositide-binding C2 domain also found in PKC isoforms and synaptotagmins. In addition, expression of PI3-kinase p170 is widespread and may indicate that the protein performs a housekeeping function in cell growth and differentiation.
Development References (2)
-
Brown RA, Ho LK, Weber-Hall SJ, Shipley JM, Fry MJ. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun. 1997; 233(2):537-544. (Biology). View Reference
-
Virbasius JV, Guilherme A, Czech MP. Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J Biol Chem. 1996; 271(23):13304-13307. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.